Loading
Immature immune cells that tumours summon to switch off T cells. Their numbers in blood predict worse immunotherapy outcomes.
Granulocytic (PMN-MDSC) and monocytic (M-MDSC) subsets; suppress T cells via arginase, iNOS, ROS, and PD-L1. Expanded by G-CSF, IL-6, and VEGF from tumours. Targets under study: CXCR2, STAT3, arginase inhibitors, PI3Kγ; also depleted by some chemotherapies (gemcitabine, 5-FU) and inhibited by PDE5 inhibitors in pilot trials. No medicine in OnCo is recorded as acting mainly on MDSCs. The four linked trials test SX-682, an oral CXCR1/2 inhibitor that blocks MDSCs from travelling into tumours in mouse models of head and neck cancer (Greene et al., Clinical Cancer Research 2020), with checkpoint inhibitors or enzalutamide.
In plain words · The signal tumours use to grow their own blood supply. Blocking it starves tumours and, surprisingly, helps immunotherapy work.
Showing the target this term concerns: VEGF / VEGFR.
Shares CD14, Tumour microenvironment (TME).
Shares CD14, Complement in cancer.
Shares The pre-metastatic niche, Complement in cancer, Nutrient competition & metabolic immunosuppression, Myeloid suppression: TAMs, MDSCs & don't-eat-me signals.
Shares Myeloid suppression: TAMs, MDSCs & don't-eat-me signals, Tumour microenvironment (TME), PD-L1.
Shares CD14, Macrophage, Nutrient competition & metabolic immunosuppression, Myeloid suppression: TAMs, MDSCs & don't-eat-me signals.
Shares Complement in cancer, Myeloid suppression: TAMs, MDSCs & don't-eat-me signals.
Shares Myeloid suppression: TAMs, MDSCs & don't-eat-me signals, Tumour microenvironment (TME).
Shares Macrophage, Myeloid suppression: TAMs, MDSCs & don't-eat-me signals, Tumour microenvironment (TME).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/